Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.122.264860 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Rofo
January 2025
Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Theranostics in nuclear oncology combines diagnostic and therapeutic procedures using radiotracers to target tumor cells. Prostate-specific membrane antigen (PSMA) is a key target in metastatic prostate cancer, and the radioligand [177Lu]Lu-PSMA-617, which binds to PSMA, has shown promising results in treating metastatic castration-resistant prostate cancer (mCRPC), leading to its approval by the European Medicines Agency in 2022.In this narrative review, the current evidence of [177Lu]Lu-PSMA-617 in mCRPC was discussed in the context of selected studies and the joint EANM/SNMMI guidelines for Lutetium-177-labeled PSMA-targeted radioligand therapy.
View Article and Find Full Text PDFJoint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0.
Eur J Nucl Med Mol Imaging
January 2025
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI.
View Article and Find Full Text PDFSNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.
J Nucl Med
January 2025
Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium; and.
Article Synopsis
Can ChatGPT help patients understand radiopharmaceutical extravasations?
Front Nucl Med
November 2024
Independent Researcher, Cary, NC, United States.
A previously published paper in the official journal of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) concluded that the artificial intelligence chatbot ChatGPT may offer an adequate substitute for nuclear medicine staff informational counseling to patients in an investigated setting of F-FDG PET/CT. To ensure consistency with the previous paper, the author and a team of experts followed a similar methodology and evaluated whether ChatGPT could adequately offer a substitute for nuclear medicine staff informational counseling to patients regarding radiopharmaceutical extravasations. We asked ChatGPT fifteen questions regarding radiopharmaceutical extravasations.
View Article and Find Full Text PDFSNMMI Procedure Standard/EANM Practice Guideline for Brain [F]FDG PET Imaging, Version 2.0.
J Nucl Med
October 2024
APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille University, Marseille, France.
PREAMBLEThe Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!